Carmat Total Liabilities
Carmat total liabilities. Based on the latest financial reports, Carmat (ALCAR) has total liabilities worth €93.56 Million EUR (≈ $109.38 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Carmat asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Carmat (2009–2024)
Total liabilities of Carmat from 2009 to 2024. This chart illustrates how Carmat's total liabilities have evolved over time, based on quarterly financial data. Explore ALCAR long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Carmat Competitors by Total Liabilities
The table below lists competitors of Carmat ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Au Gold Corp
V:AUGC
|
Canada | CA$147.45K |
|
Domec Compania de Artefactos Domesticos SAIC y F
BA:DOME
|
Argentina | AR$4.26 Billion |
|
Canadian Premium Sand Inc
V:CPS
|
Canada | CA$6.21 Million |
|
Noble Financials SA
WAR:IBS
|
Poland | zł70.99 Million |
|
Gema Grahasarana Tbk
JK:GEMA
|
Indonesia | Rp792.05 Billion |
|
Prakash Steelage Limited
NSE:PRAKASHSTL
|
India | Rs266.21 Million |
|
RECYCLICO BATTERY METALS
F:ID4
|
Germany | €4.43 Million |
|
Curative Biotechnology Inc
NYSE MKT:CUBT
|
USA | $8.37 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Carmat's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Carmat.
Liquidity & Leverage Metrics
Carmat Total Liabilities Ratios Explained
Carmat total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Carmat's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Carmat (2009–2024)
The table below shows the annual total liabilities of Carmat from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €93.56 Million ≈ $109.38 Million |
-3.38% |
| 2023-12-31 | €96.83 Million ≈ $113.21 Million |
+16.29% |
| 2022-12-31 | €83.27 Million ≈ $97.35 Million |
+0.77% |
| 2021-12-31 | €82.63 Million ≈ $96.60 Million |
+58.85% |
| 2020-12-31 | €52.02 Million ≈ $60.81 Million |
+29.37% |
| 2019-12-31 | €40.21 Million ≈ $47.01 Million |
+146.81% |
| 2018-12-31 | €16.29 Million ≈ $19.05 Million |
+28.87% |
| 2017-12-31 | €12.64 Million ≈ $14.78 Million |
+46.98% |
| 2016-12-31 | €8.60 Million ≈ $10.06 Million |
+18.69% |
| 2015-12-31 | €7.25 Million ≈ $8.47 Million |
+15.43% |
| 2014-12-31 | €6.28 Million ≈ $7.34 Million |
-57.46% |
| 2013-12-31 | €14.76 Million ≈ $17.25 Million |
+51.25% |
| 2012-12-31 | €9.76 Million ≈ $11.41 Million |
-7.40% |
| 2011-12-31 | €10.54 Million ≈ $12.32 Million |
+89.66% |
| 2010-12-31 | €5.55 Million ≈ $6.49 Million |
+180.91% |
| 2009-12-31 | €1.98 Million ≈ $2.31 Million |
-- |
About Carmat
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.